Robuta

A new test has helped reduce the risk of death in lung cancer patients in a recent clinical trial.

Background: Cell-free DNA (cfDNA) holds promise as a tumor marker of clinical importance. We aimed to investigate the prognostic value of baseline cfDNA in...

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (An Expanded Lung-MAP Treatment Trial)

Body mass index (BMI) influences the prognosis of patients with non-small cell lung cancer (NSCLC), including both early-stage and late-stage NSCLC patients...

The U.S. Food & Drug Administration has approved a new drug to treat patients with a type of advanced lung cancer that tends to have a poor prognosis.

A new study by UCLA scientists has found that the breakthrough immunotherapy drug pembrolizumab can be more effective in improving survival in people with...

Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Small-Cell Lung Cancer.

The real-world, retrospective, NEROnE registry investigated the impact of next-generation sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC)...

Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of...

This study demonstrates the potential of a decision support tool to limit late SACT administration in patients with cancer. Further work is warranted to refine...

Daijiworld Media Network - Riyadh Riyadh, Jan 17: The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva, a groundbreaking...

Daijiworld Media Network - Riyadh Riyadh, Jan 17: The Saudi Food and Drug Authority (SFDA) has granted conditional approval for Anktiva, a groundbreaking...